Gilead Sciences Inc (GILD)
65.54
+0.76
(+1.17%)
USD |
NASDAQ |
May 06, 16:00
65.45
-0.09
(-0.14%)
After-Hours: 20:00
Gilead Sciences SG&A Expense (Annual): 6.09B for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 6.09B |
| December 31, 2022 | 5.673B |
| December 31, 2021 | 5.246B |
| December 31, 2020 | 5.151B |
| December 31, 2019 | 4.381B |
| December 31, 2018 | 4.056B |
| December 31, 2017 | 3.878B |
| December 31, 2016 | 3.398B |
| December 31, 2015 | 3.426B |
| December 31, 2014 | 2.983B |
| December 31, 2013 | 1.699B |
| December 31, 2012 | 1.461B |
| December 31, 2011 | 1.242B |
| December 31, 2010 | 1.044B |
| December 31, 2009 | 946.69M |
| December 31, 2008 | 797.34M |
| December 31, 2007 | 705.74M |
| Date | Value |
|---|---|
| December 31, 2006 | 573.66M |
| December 31, 2005 | 381.28M |
| December 31, 2004 | 307.10M |
| December 31, 2003 | 250.16M |
| December 31, 2002 | 181.30M |
| December 31, 2001 | 125.14M |
| December 31, 2000 | 82.02M |
| December 31, 1999 | 78.30M |
| December 31, 1998 | 78.20M |
| December 31, 1997 | 70.60M |
| December 31, 1996 | 26.70M |
| December 31, 1995 | 34.70M |
| March 31, 1995 | 9.70M |
| March 31, 1994 | 7.60M |
| March 31, 1993 | 22.40M |
| March 31, 1992 | 9.10M |
| March 31, 1991 | 6.10M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
4.381B
Minimum
2019
6.09B
Maximum
2023
5.308B
Average
5.246B
Median
2021
SG&A Expense (Annual) Benchmarks
| Amgen Inc | 6.179B |
| CymaBay Therapeutics Inc (DELISTED) | 51.95M |
| Bristol-Myers Squibb Co | 7.772B |
| Eli Lilly and Co | 6.941B |
| Xilio Therapeutics Inc | 27.00M |